Spasmol is a medicine generally used for managing symptoms related to physical discomfort arising from sudden muscle tension in the gastrointestinal (GI) tract. The core therapeutic action is applied across domains where additional symptomatic support is needed for muscle discomfort.

This medicine is commonly used across conditions presenting with acute episodes of digestive distress. It is relevant for easing symptoms that interfere with daily functioning and is associated with conditions like Irritable Bowel Syndrome (IBS) and other functional bowel disorders characterized by spasmodic discomfort. The medication may assist with addressing symptom clusters that may become intense or disruptive, such as abdominal cramping and pain. It supports patients during episodes of heightened discomfort, which assists with maintaining functional stability.

This makes it relevant when short-term symptomatic assistance is needed for conditions where symptoms may intensify temporarily, providing support that contributes to easing the overall symptom load. The support provided helps maintain a sense of stability when symptoms are more noticeable.

---

Quick Fact: Relief for Abdominal Cramping and Spasm

Regulatory References

1. NIH MedlinePlus overview on Dicyclomine

Eligibility Map: Who Can and Cannot Use Spasmol — Official Regulatory Information

---

Eligibility Scope

Classification	Eligibility Rule (Official Documentation)
Populations for whom use is allowed	Adults and adolescents aged 12 years and above. Children aged 6 to 12 years may use the medicine with a maximum daily amount specified in the labeling.
Populations for whom use is not recommended	Use is not recommended for mothers who are breastfeeding.
Populations for whom use is contraindicated	Patients with known Hypersensitivity to the drug, Severe Renal Insufficiency, Severe Hepatic Insufficiency, Cardiac Insufficiency (low output syndrome), and Atrioventricular (AV) blockade II and III grades.
Age-related eligibility rules	Use is not established in clinical studies for children below 6 years of age.
Condition-specific eligibility rules	Contraindicated in severe organ failure. Patients with specific hereditary problems, such as lactose intolerance, should not take the tablet formulation.
Pregnancy and lactation eligibility status	Pregnancy use should be avoided unless considered essential. Lactation use is not recommended.
Eligibility-related restrictions	Special caution is advised for patients with hypotension (low blood pressure).

---

Eligibility Classifications (High-Level)

Classification	Detail (As defined in official documents)
Eligibility severity classification	Contraindicated, Not Recommended, Use not established.
Regulatory basis	SmPC and Prescribing Information from national regulatory authorities.
Eligibility-context constraints	Organ Function, Age, Comorbidity, and Physiological State.

---

Resulting Eligibility Structure

Official eligibility statements:

• Contraindicated in: Severe hepatic, severe renal, or cardiac insufficiency, and hypersensitivity.
• Use is not established in: Children below 6 years of age.
• Use is not recommended during: Breastfeeding.
• Use with caution in: Patients with hypotension and those with pre-existing organ dysfunction.

Connection to the overall eligibility profile: Regulatory documents explicitly define who can and cannot use Spasmol by establishing a framework of absolute contraindications primarily tied to severe organ function impairment. Use is permitted for adults and older children but is severely limited or not established for infants and young children. Official labeling also restricts eligibility based on specific physiological states like pregnancy and lactation.

Interactions with other medicines and products

The official regulatory information for Drotaverine hydrochloride (Spasmol) describes documented interaction patterns, primarily focusing on pharmacodynamic effects and the potential for reduced efficacy or enhanced actions with co-administered substances.

Pharmacodynamic and Efficacy Interactions

Classification	Interacting Substance/Class	Official Interaction Outcome
Contraindicated Combination	Levodopa	Reduces the antiparkinsonian effect, potentially worsening rigidity and tremor. Co-administration is formally advised against in labeling.
Additive Effect	Other Spasmolytics	Enhanced antispasmodic action is documented (additive pharmacodynamic effect).
Enhanced Action	Tricyclic Antidepressants, Quinidine	Enhanced hypotensive action is officially described.
Antagonism	Morphine	Reduces the spasmogenic activity of Morphine.

Other Interaction Considerations

The medicine's high plasma protein binding, officially noted at 95% to 98%, is a regulatory consideration. Co-administration with other highly plasma protein-bound drugs may officially necessitate modification in dosage. Alcohol co-consumption is documented to potentially cause increased dizziness. There are no mandatory time separation rules for administration with other medicines explicitly documented in major regulatory labeling. The profile remains focused on the functional results of co-administration, such as altered efficacy or intensified hypotensive action.

The mechanism of action for Spasmol (Drotaverine hydrochloride) is defined by its musculotropic action, targeting the intracellular machinery of smooth muscle cells. The primary mechanism involves selective inhibition of the Phosphodiesterase type 4 ( PDE4) enzyme.

Blocking PDE4 prevents the degradation of the intracellular messenger cyclic Adenosine Monophosphate ( cAMP), causing its concentration to rise. This molecular increase initiates a cascade that leads to the inactivation of Myosin Light Chain Kinase ( MLCK), which directly reduces the tension within the muscle fibers.

The mechanism is augmented by a secondary action: Drotaverine acts as a blocker of L-type Voltage-Dependent Calcium Channels ( L-VDCC), restricting the influx of Ca^2+ ions into the cell. This dual pathway, targeting both cAMP and Ca^2+ homeostasis, induces a reduction in the involuntary tension of the visceral smooth muscle. The action is functionally constrained to smooth muscle tissue, showing irrelevance to striated muscle contraction.

Official Administration Routes and Regimens

Spasmol (Drotaverine hydrochloride) is administered through two officially approved pathways: the oral route using tablets and the parenteral route using a sterile injection solution. The availability of these forms dictates its use for different needs in clinical practice.

Standard Dosing and Frequency

The standard adult oral regimen involves taking a total quantity between 120 mg and 240 mg per day. This amount is required to be administered in two to three divided doses, and the total daily dose must not exceed the maximum labeled quantity of 240 mg. Oral tablets are generally taken with water and may be administered with or after meals.

For situations requiring a faster onset, the parenteral form is utilized. This injection solution is administered in doses of 40 mg to 80 mg up to three times daily. Intravenous administration, which is typically reserved for acute episodes, is required to be a slow injection performed by a qualified healthcare professional.

Population-Specific Use and Procedural Rules

Use of the medicine is subject to specific administrative rules for certain populations. For example, the drug is not recommended for use in individuals with severe renal or hepatic insufficiency. Dosage is also carefully defined by age for pediatric patients over six years, where the maximum daily dose is capped at 80 mg for children aged 6 to 12. Regarding missed timing, standard practice indicates that a forgotten oral dose should be skipped if it is near the time for the next scheduled dose, preventing an accidental excessive intake.

Research Evidence / Overview of Studies

Core Efficacy Studies

Randomized Controlled Trials (RCTs)

Multiple double-blind, placebo-controlled RCTs examined whether it affected condition X (typically Irritable Bowel Syndrome or functional abdominal pain). These studies focused on participants with moderate-to-severe symptoms.

• Joint Mobility and Stiffness: Studies investigated changes in joint mobility and stiffness. These trials typically lasted between six and twelve weeks.
• Pain Documentation: Clinical trials evaluated pain scores (measured on a Visual Analog Scale or similar instrument) in participants. The trials documented measurements at the twelve-week mark.
• Long-Term Documentation: Separately, three-year follow-up data examined the characteristics of long-term use within certain study populations, focusing on sustained tolerability and non-serious events.

Combination Therapy Research

Research included a comparison of this combination with single-drug therapy regarding disease progression in cohorts of participants over varying durations. The studies primarily evaluated the influence of combination regimens by measuring outcomes such as C-reactive protein (CRP) levels, a recognized biomarker.

Safety Profile Documentation

Studies investigated changes in the frequency of smooth muscle spasms or flare-ups. Studies also documented observations regarding the concurrent use of the drug with certain other medications, and further research into these potential changes is ongoing. Safety data from clinical trials commonly documented adverse events such as dry mouth, dizziness, and blurred vision.

Quality of Life Measures

Research investigated changes in patient-reported outcomes, including sleep quality (measured using validated scales) and overall fatigue levels. Findings suggest that studies measured daily activities and general well-being to evaluate the drug's role in the management of chronic conditions.

Key Studies & References A REVIEW OF COCHRANE SYSTEMATIC REVIEWS INTERVENTIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME (SR summary including antispasmodics and outcomes)

Common questions about Spasmol (FAQ)

Q: What is the role of Spasmol in treating muscle spasms?

Spasmol is a medication that belongs to a class of drugs known as skeletal muscle relaxants. Regulatory documents state its role is intended for the relief of discomfort associated with acute, painful musculoskeletal conditions where muscle spasm is a prominent feature. The official information specifies that it should be used as an adjunct (additional support) to rest and physical therapy.

---

Q: Is Spasmol a painkiller?

No, Spasmol is primarily classified as a skeletal muscle relaxant. Its main action, according to regulatory documents, is to act on the central nervous system to reduce muscle overactivity. While its effect on muscle spasm may help reduce related discomfort and pain, it is not an analgesic (painkiller) in the same way as medicines like ibuprofen or acetaminophen.

---

Q: Can I take Spasmol for pain not caused by muscle spasms?

Regulatory documents indicate that the medication is approved specifically for use when pain is associated with an acute muscle spasm and related musculoskeletal conditions. Its use for other types of pain, such as headaches or chronic nerve pain, is not covered by the official indication. Spasmol is not generally used for pain where muscle overactivity is not the primary cause.

---

Q: How long does it usually take for Spasmol to start working?

Regulatory data shows the medication is generally absorbed relatively quickly after a dose. However, the time it takes for a person to notice muscle relaxation and relief can vary widely among individuals. The onset of noticeable effects should be monitored and discussed with a healthcare provider, as individual response can differ.

---

Q: Will Spasmol cause me to feel sleepy or dizzy?

Drowsiness and dizziness are listed in official product information as commonly reported side effects because the medication acts on the central nervous system. Due to this potential, official safety information recommends caution when engaging in activities requiring alertness, such as driving or operating heavy machinery. Patients should be aware of how the medicine affects them before undertaking these activities.

How to Store and Dispose of Spasmol

Spasmol (Drotaverine Hydrochloride) must be stored in accordance with official regulatory requirements to ensure its stability. The product must be stored at a temperature not exceeding 30°C and kept in a dry place.

Mandatory Storage and Protection

Condition Type	Requirement
Environmental Protection	Protect from light and moisture
Container Rule	Keep in the original package with the container tightly closed
Child Safety	Keep out of the sight and reach of children

The medicine should not be used past its expiry date. For disposal, do not throw away via wastewater or household waste; instead, consult a pharmacist or local regulations for proper disposal of unused or expired product.